Your AI-Trained Oncology Knowledge Connection!

Sebastian C. Schmid, MD

home / authors / sebastian-c-schmid-md

Articles

Sebastian C. Schmid, MD

Dr. Schmid on Next Steps for the RACE IT Trial in Urothelial Carcinoma

Sebastian C. Schmid, MD
December 1st 2022

Sebastian C. Schmid, MD, discusses the future of the phase 2 RACE IT trial in urothelial carcinoma.

Read More

Sebastian C. Schmid, MD

Dr. Schmid on the Rationale for the RACE IT Trial in Advanced Urothelial Carcinoma

Sebastian C. Schmid, MD
November 15th 2022

Sebastian C. Schmid, MD, discusses the rationale for the phase 2 RACE IT trial in urothelial carcinoma.

Read More

Sebastian C. Schmid, MD

Dr. Schmid on the Use of Preoperative Radiation Therapy in Urothelial Carcinoma

Sebastian C. Schmid, MD
September 28th 2022

Sebastian C. Schmid, MD, discusses the use of preoperative radiation therapy plus immunotherapy in urothelial carcinoma.

Read More

Latest Updated Articles

RLY-2608
Published: January 22nd 2025 | Updated: February 14th 2025
Efficacy of RLY-2608, a mutant-selective PI3Kα inhibitor, in patients with PIK3CA-mutant HR+HER2- advanced breast cancer: ReDiscover trial
Tagraxofusp Achieves Anti-tumor Activity With Rapid Restoration of Normal Hematopoiesis in Treatment-Naïve Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Subanalysis of a Pivotal Trial
Published: February 11th 2025 | Updated: February 14th 2025
Tagraxofusp Achieves Anti-Tumor Activity with Rapid Restoration of Normal Hematopoiesis in Treatment-Naïve Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Subanalysis of a Pivotal Trial
2 expert is featured in this series.
Published: December 24th 2024 | Updated: January 28th 2025
Brief Overview of Synovial Sarcoma: What It Is, Clinical Presentation and Diagnosis
Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer
Published: December 17th 2024 | Updated: January 16th 2025
Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer
Ropeginterferon Alfa-2b in Essential Thrombocytopenia | Image Credit: © Tatiana Shepeleva - stock.adobe.com
Published: January 6th 2025 | Updated: January 8th 2025
Second-Line Ropeginterferon Alfa-2b Boosts Responses in Essential Thrombocythemia
OncLive co-hosts Kristie L. Kahl and Andrew Svonavec highlight abstracts for medical oncologists to look out for at the upcoming ASH Annual Meeting in San Diego, with some additional tidbits to round out the main event.
Published: December 3rd 2024 | Updated: December 6th 2024
ASH 2024 Preview for Medical Oncologists: The Show and After Show